RESUMO
This study examined the association of socio-economic factors and the structure of primary care centres (PCCs) with measles, mumps, and rubella (MMR) vaccination coverage among the 8-year-old population in Catalonia, Spain. We conducted an ecological study to retrospectively assess the MMR vaccination-recorded status of children born in 2012, using public health data extracted in December 2020. For each of 300 PCCs serving 70,498 children, we calculated vaccination coverage rates from electronic health records and linked these rates to a composite deprivation index corresponding to the territory served by each PCC. We identified a relationship between unfavourable socio-economic factors and higher recorded vaccination coverage. On average, directly managed PCCs had higher vaccination coverage rates than indirectly managed PCCs. Greater utilisation of primary care services by the population was also associated with higher vaccination coverage rates. Further research is needed to generate knowledge valuable for informing more equitable child-vaccination service delivery models.
Assuntos
Vacina contra Sarampo-Caxumba-Rubéola , Atenção Primária à Saúde , Fatores Socioeconômicos , Cobertura Vacinal , Humanos , Espanha , Atenção Primária à Saúde/estatística & dados numéricos , Vacina contra Sarampo-Caxumba-Rubéola/administração & dosagem , Criança , Cobertura Vacinal/estatística & dados numéricos , Estudos Retrospectivos , Feminino , Masculino , Sarampo/prevenção & controle , Sarampo/epidemiologia , Rubéola (Sarampo Alemão)/prevenção & controle , Caxumba/prevenção & controle , Caxumba/epidemiologia , Vacinação/estatística & dados numéricosRESUMO
Objectives. To assess the impact of Washington State's 2019 Engrossed House Bill (EHB) 1638-which removed measles, mumps, and rubella (MMR) personal belief exemptions-on MMR vaccine series completion and exemption rates in K-12 students. Methods. We used interrupted time-series analyses to examine changes in MMR vaccine series completion rates before and after EHB 1638 was passed and the χ2 test for differences in exemption rates. Results. EHB 1638 implementation was associated with a 5.4% relative increase in kindergarten MMR vaccine series completion rates (95% confidence interval = 3.8%, 7.1%; P ≤ .001), and results were similar with Oregon as a control state (no change observed in Oregon; P = .68). MMR exemptions overall decreased 41% (from 3.1% in 2018-2019 to 1.8% in 2019-2020; P ≤ .001), and religious exemptions increased 367% (from 0.3% to 1.4%; P ≤ .001). Conclusions. EHB 1638 was associated with an increase in MMR vaccine series completion rates and a decrease in any MMR exemption. However, effects were partially offset by an increase in religious exemption rates. Public Health Implications. Removal of personal belief exemptions for the MMR immunization requirement only may be an effective approach to increase MMR vaccine coverage rates statewide and among underimmunized communities. (Am J Public Health. 2023;113(7):795-804. https://doi.org/10.2105/AJPH.2023.307285).
Assuntos
Sarampo , Caxumba , Rubéola (Sarampo Alemão) , Humanos , Vacina contra Sarampo-Caxumba-Rubéola , Washington , Caxumba/prevenção & controle , Vacinação , Política de Saúde , Sarampo/prevenção & controle , Instituições Acadêmicas , Rubéola (Sarampo Alemão)/prevenção & controleRESUMO
OBJECTIVES: Economic evaluations of vaccines should accurately represent all relevant economic and health consequences of vaccination, including losses due to adverse events following immunization (AEFI). We investigated to what extent economic evaluations of pediatric vaccines account for AEFI, which methods are used to do so and whether inclusion of AEFI is associated with study characteristics and the vaccine's safety profile. METHODS: A systematic literature search (MEDLINE, EMBASE, Cochrane Systematic Reviews and Trials, Database of the Centre for Reviews and Dissemination of the University of York, EconPapers, Paediatric Economic Database Evaluation, Tufts New England Cost-Effectiveness Analysis Registry, Tufts New England Global Health CEA, International Network of Agencies for Health Technology Assessment Database) was performed for economic evaluations published between 2014 and 29 April 2021 (date of search) pertaining to the five groups of pediatric vaccines licensed in Europe and the United States since 1998: the human papillomavirus (HPV) vaccines, the meningococcal vaccines (MCV), the measles-mumps-rubella-varicella (MMRV) combination vaccines, the pneumococcal conjugate vaccines (PCV) and the rotavirus vaccines (RV). Rates of accounting for AEFI were calculated, stratified by study characteristics (e.g., region, publication year, journal impact factor, level of industry involvement) and triangulated with the vaccine's safety profile (Advisory Committee on Immunization Practices [ACIP] recommendations and information on safety-related product label changes). The studies accounting for AEFI were analyzed in terms of the methods used to account for both cost and effect implications of AEFI. RESULTS: We identified 112 economic evaluations, of which 28 (25%) accounted for AEFI. This proportion was significantly higher for MMRV (80%, four out of five evaluations), MCV (61%, 11 out of 18 evaluations) and RV (60%, nine out of 15 evaluations) compared to HPV (6%, three out of 53 evaluations) and PCV (5%, one out of 21 evaluations). No other study characteristics were associated with a study's likelihood of accounting for AEFI. Vaccines for which AEFI were more frequently accounted for also had a higher frequency of label changes and a higher level of attention to AEFI in ACIP recommendations. Nine studies accounted for both the cost and health implications of AEFI, 18 studies considered only costs and one only health outcomes. While the cost impact was usually estimated based on routine billing data, the adverse health impact of AEFI was usually estimated based on assumptions. DISCUSSION: Although (mild) AEFI were demonstrated for all five studied vaccines, only a quarter of reviewed studies accounted for these, mostly in an incomplete and inaccurate manner. We provide guidance on which methods to use to better quantify the impact of AEFI on both costs and health outcomes. Policymakers should be aware that the impact of AEFI on cost-effectiveness is likely to be underestimated in the majority of economic evaluations.
Assuntos
Varicela , Sarampo , Caxumba , Neisseria meningitidis , Infecções por Papillomavirus , Vacinas contra Rotavirus , Rotavirus , Rubéola (Sarampo Alemão) , Criança , Humanos , Varicela/prevenção & controle , Análise Custo-Benefício , Streptococcus pneumoniae , Papillomavirus Humano , Caxumba/prevenção & controle , Vacinação , Imunização , Sarampo/prevenção & controle , Vacinas contra Rotavirus/efeitos adversos , Rubéola (Sarampo Alemão)/prevenção & controleRESUMO
BACKGROUND: Infection is believed to be a potential trigger for inflammatory bowel disease (IBD). Whether vaccination against childhood infections including measles, mumps, and rubella may reduce risk of IBD is uncertain. METHODS: We conducted a retrospective cohort study using de-identified claims data from a national private payer (Optum Clinformatics Data Mart). Eligible infants were born between 2001 and 2018 and were continuously enrolled with medical and pharmacy coverage from birth for at least 2 years (nâ =â 1 365 447). Measles, mumps, and rubella vaccination or MMR is administered beginning at 12 months of age. Cox proportional hazard regression models were used to compare time with incident disease in children by category of vaccination, after adjustment for sex, birth year, region of country, history of allergy to vaccines, and seizure history. RESULTS: The incidence of early pediatric IBD increased between 2001 and 2018. Ten percent (nâ =â 141 230) of infants did not receive MMR, and 90% (nâ =â 1 224 125) received at least 1 dose of MMR. There were 334 cases of IBD, 219 cases of Crohn's disease, and 164 cases of ulcerative colitis. Children who had received at least 1 dose of MMR had lower risk for IBD than children who did not (hazard ratio, 0.71; 95% confidence interval, 0.59-0.85). These associations did not change after further adjustment for childhood comorbid conditions, preterm birth, or older siblings affected with IBD. Similar associations were observed for MMR with Crohn's disease and ulcerative colitis, although these did not reach statistical significance. CONCLUSION: MMR is associated with decreased risk for childhood IBD.
Childhood vaccination against measles, mumps, and rubella was associated with decreased risk of childhood inflammatory bowel disease in a national administrative claims database.
Assuntos
Colite Ulcerativa , Doença de Crohn , Doenças Inflamatórias Intestinais , Sarampo , Caxumba , Nascimento Prematuro , Rubéola (Sarampo Alemão) , Recém-Nascido , Lactente , Feminino , Criança , Humanos , Estudos Retrospectivos , Vacina contra Sarampo-Caxumba-Rubéola , Caxumba/prevenção & controle , Sarampo/epidemiologia , Sarampo/prevenção & controle , Rubéola (Sarampo Alemão)/prevenção & controle , Vacinação , Seguro Saúde , Anticorpos AntiviraisRESUMO
OBJECTIVES: To quantify the effect of the COVID-19 pandemic on the timeliness of, and geographical and sociodemographic inequalities in, receipt of first measles, mumps and rubella (MMR) vaccination. DESIGN: Longitudinal study using primary care electronic health records. SETTING: 285 general practices in North East London. PARTICIPANTS: Children born between 23 August 2017 and 22 September 2018 (pre-pandemic cohort) or between 23 March 2019 and 1 May 2020 (pandemic cohort). MAIN OUTCOME MEASURE: Receipt of timely MMR vaccination between 12 and 18 months of age. METHODS: We used logistic regression to estimate the ORs (95% CIs) of receipt of a timely vaccination adjusting for sex, deprivation, ethnic background and Clinical Commissioning Group. We plotted choropleth maps of the proportion receiving timely vaccinations. RESULTS: Timely MMR receipt fell by 4.0% (95% CI: 3.4% to 4.6%) from 79.2% (78.8% to 79.6%) to 75.2% (74.7% to 75.7%) in the pre-pandemic (n=33 226; 51.3% boys) and pandemic (n=32 446; 51.4%) cohorts, respectively. After adjustment, timely vaccination was less likely in the pandemic cohort (0.79; 0.76 to 0.82), children from black (0.70; 0.65 to 0.76), mixed/other (0.77; 0.72 to 0.82) or with missing (0.77; 0.74 to 0.81) ethnic background, and more likely in girls (1.07; 1.03 to 1.11) and those from South Asian backgrounds (1.39; 1.30 to 1.48). Children living in the least deprived areas were more likely to receive a timely MMR (2.09; 1.78 to 2.46) but there was no interaction between cohorts and deprivation (Wald statistic: 3.44; p=0.49). The proportion of neighbourhoods where less than 60% of children received timely vaccination increased from 7.5% to 12.7% during the pandemic. CONCLUSIONS: The COVID-19 pandemic was associated with a significant fall in timely MMR receipt and increased geographical clustering of measles susceptibility in an area of historically low and inequitable MMR coverage. Immediate action is needed to avert measles outbreaks and support primary care to deliver timely and equitable vaccinations.
Assuntos
COVID-19 , Sarampo , Caxumba , Rubéola (Sarampo Alemão) , Masculino , Criança , Feminino , Humanos , Caxumba/epidemiologia , Caxumba/prevenção & controle , Pandemias , COVID-19/epidemiologia , COVID-19/prevenção & controle , Estudos Longitudinais , Registros Eletrônicos de Saúde , Londres/epidemiologia , Rubéola (Sarampo Alemão)/epidemiologia , Rubéola (Sarampo Alemão)/prevenção & controle , Sarampo/epidemiologia , Sarampo/prevenção & controle , VacinaçãoRESUMO
We conducted a cross-sectional study using a structured questionnaire in three major Japanese cities from August 03 to 24, 2020 to clarify the current situation of health checkups, including vaccine-preventable diseases (VPDs), among international students at Japanese universities (JUs) and Japanese language schools (JLSs). The total response rate was 36%: 69 JUs (31%) and 137 JLSs (39%). Over 90% of these institutions conducted chest X-ray screening for tuberculosis among their students, whereas only 24.6% of JUs and 15.3% of JLSs performed general blood tests for health screening. Only 14.5% and 2.2% of the JUs and JLSs, respectively, required the submission of vaccination or antibody certificates for admission. The difficulties in requesting vaccination certificates from international students are due to poor legal requirements and concerns about rising costs for schools. From 2017 to 2019, 183 international students, principally from East Asia and Southeast Asia, were infected with VPDs, particularly tuberculosis (99 cases) and varicella (71 cases). Whereas the majority of Japanese educational institutions screen international students for tuberculosis (TB) at admission, only a few institutions request proof of antibody testing relating to other VPDs or of vaccination. These findings will help formulate guidelines for checkups related to vaccination for international students required to protect the educational institutions in Japan from the spread of VPDs. In addition, providing multifaceted social support, including financial compensation for institutions and enhanced international students' health issues, would be helpful.
Assuntos
Varicela , Sarampo , Caxumba , Rubéola (Sarampo Alemão) , Tuberculose , Doenças Preveníveis por Vacina , Humanos , Estudos Transversais , Doenças Preveníveis por Vacina/prevenção & controle , Varicela/prevenção & controle , Vacinação , Medição de Risco , Japão/epidemiologia , Sarampo/prevenção & controle , Rubéola (Sarampo Alemão)/prevenção & controle , Caxumba/prevenção & controleRESUMO
BACKGROUND: The most common preventative measure against mumps is vaccination with mumps vaccine. Over 122 countries have implemented mumps vaccine routine immunization programs, mostly via Measles-Mumps-Rubella (MMR) vaccine. In Japan, the unexpectedly high incidence of aseptic meningitis caused by mumps vaccine led to the discontinuation of the MMR national vaccination program in 1993, inadvertently resulting in the re-emergence of mumps. Plans of introducing monovalent mumps vaccine into routine vaccination schedule have become one of the emerging topics in health policy that has warranted the need in evaluating its value for money. METHODS: We conducted cost-effectiveness analyses with Markov model and calculated incremental cost-effectiveness ratios (ICERs) of two different vaccination programs (a single-dose program at one-year-old, a two-dose program with second dose uptakes at five) compared to status quo from both payers' and societal perspectives. Transition probabilities and utility weights in estimating quality-adjusted life-year (QALY), and disease treatment costs were either estimated or obtained from literature. Costs per vaccination were assumed at ¥6140 (US$58;1US$ = ¥106). RESULTS: Both programs reduce disease treatment costs compared to status quo, while the reduction cannot offset vaccination cost. ICER of either program is found to be under ¥5,000,000 (US$47,170)/QALY willingness-to-pay (WTP) threshold from either perspective. Results of probabilistic sensitivity analyses expressed by net monetary benefit indicated that at the WTP threshold, the acceptability is at 92.6% for two-dose vaccination program, 0% for single-dose vaccination program, and 7.4% for current no vaccination program. Two-dose program was optimal among the alternatives. One-way sensitivity analyses revealed that proportion of mumps-related hearing loss among mumps cases and vaccine effectiveness (VE) were key variables in changing the ICERs. CONCLUSION: Routine vaccination program of single- and two-dose programs were cost-effective from both payers' and societal perspectives. Between the two, the two-dose vaccination program was observed to be more favorable.
Assuntos
Caxumba , Criança , Análise Custo-Benefício , Humanos , Programas de Imunização , Lactente , Japão/epidemiologia , Vacina contra Sarampo-Caxumba-Rubéola , Caxumba/epidemiologiaRESUMO
Mumps cases were reported frequently when a routine dose measles-mumps-rubella(MMR) achieved high coverage in Quzhou. The supplementary immunization activities (SIA) using measles mumps (MM) was conducted to control mumps outbreaks. The effectiveness of one and two doses of mumps-containing vaccine (MuCV) was assessed using surveillance data in this study. Mumps cases and immunization information were retrieved from the National Notifiable Disease Reporting System (NNDRS) and the Zhejiang Provincial Immunization Information System (ZJIIS), respectively. Mumps cases of children born from 2006 to 2010 were included. Vaccine effectiveness by dose was calculated using the screening method. A total of 956 mumps cases were identified, of whom 754 (78.9%) had received one dose of MuCV; 108 (11.3%) had received two doses; 94 (9.8%) were unvaccinated. The coverage of one-dose MuCV in the 2006-2010 birth cohorts ranged from 91.6% to 98.9%. Except the 2009 birth cohort in which the coverage of two doses of MuCV was 55.1%, the others were less than 10%. Vaccine effectiveness (VE) of one dose ranged from 47.4% to 86.0%, while VE of two doses ranged from 64.0% to 92.4%. The VE of one and two doses of MuCV waned over time, but the VE of two doses was consistently higher than that of one dose in the same period. The vaccine schedule with two-dose MMR should be implemented among children in Quzhou. The optimal age for the second dose needs to be further evaluated.
Assuntos
Sarampo , Caxumba , Rubéola (Sarampo Alemão) , Criança , Humanos , Lactente , Vacina contra Caxumba , Caxumba/epidemiologia , Caxumba/prevenção & controle , Eficácia de Vacinas , Sarampo/prevenção & controle , Esquemas de Imunização , China/epidemiologia , Vacina contra Sarampo-Caxumba-Rubéola , Rubéola (Sarampo Alemão)/prevenção & controleRESUMO
BACKGROUND: Pediatric international travelers account for nearly half of measles importations in the United States. Over one third of pediatric international travelers depart the United States without the recommended measles-mumps-rubella (MMR) vaccinations: 2 doses for travelers ≥12 months and 1 dose for travelers 6 to <12 months. METHODS: We developed a model to compare 2 strategies among a simulated cohort of international travelers (6 months to <6 years): (1) No pretravel health encounter (PHE): travelers depart with baseline MMR vaccination status; (2) PHE: MMR-eligible travelers are offered vaccination. All pediatric travelers experience a destination-specific risk of measles exposure (mean, 30 exposures/million travelers). If exposed to measles, travelers' age and MMR vaccination status determine the risk of infection (range, 3%-90%). We included costs of medical care, contact tracing, and lost wages from the societal perspective. We varied inputs in sensitivity analyses. Model outcomes included projected measles cases, costs, and incremental cost-effectiveness ratios ($/quality-adjusted life year [QALY], cost-effectiveness threshold ≤$100 000/QALY). RESULTS: Compared with no PHE, PHE would avert 57 measles cases at $9.2 million/QALY among infant travelers and 7 measles cases at $15.0 million/QALY among preschool-aged travelers. Clinical benefits of PHE would be greatest for infants but cost-effective only for travelers to destinations with higher risk for measles exposure (ie, ≥160 exposures/million travelers) or if more US-acquired cases resulted from an infected traveler, such as in communities with limited MMR coverage. CONCLUSIONS: Pretravel MMR vaccination provides the greatest clinical benefit for infant travelers and can be cost-effective before travel to destinations with high risk for measles exposure or from communities with low MMR vaccination coverage.
Assuntos
Sarampo , Caxumba , Rubéola (Sarampo Alemão) , Criança , Pré-Escolar , Análise Custo-Benefício , Humanos , Lactente , Sarampo/prevenção & controle , Vacina contra Sarampo-Caxumba-Rubéola , Caxumba/prevenção & controle , Rubéola (Sarampo Alemão)/prevenção & controle , Estados Unidos/epidemiologia , VacinaçãoRESUMO
Mumps remains endemic in Fiji, with 7802 cases reported between 2016 and 2018. The introduction of mumps vaccination has been discouraged due to perceptions of mumps as a self-limited disease and the perceived high cost of mumps vaccines. We estimated the benefits and costs of introducing a mumps vaccination program in Fiji. First, we estimated the burden of mumps and mumps-related complications in Fiji based on the reported cases in the Fiji National Notifiable Disease Surveillance System between 2016 and 2018. We then developed a static simulation model with stable mumps herd immunity after routine measles-mumps-rubella (MMR) vaccination. Finally, we compared the estimated economic burden of mumps with current MR vaccination and the assumptive burden of the stable-state simulation model after routine MMR vaccination. The benefit-cost ratios (BCRs) were 2.65 from the taxpayer view and 3.00 from the societal view. A probabilistic sensitivity analysis indicated that the 1st and 99th percentiles of BCRs were 1.4 and 5.2 from the taxpayer's perspective and 1.5 and 6.1 from the societal perspective. From both the taxpayer and societal perspectives, the probability of BCRs greater than 1.0 was 100%. A routine MMR program has value for money from both the taxpayer and societal perspectives. MMR vaccination should be urgently introduced in Fiji.
Assuntos
Sarampo , Caxumba , Rubéola (Sarampo Alemão) , Anticorpos Antivirais , Fiji/epidemiologia , Humanos , Sarampo/prevenção & controle , Vacina contra Sarampo-Caxumba-Rubéola , Caxumba/epidemiologia , Caxumba/prevenção & controle , VacinaçãoRESUMO
OBJECTIVES: This study investigates measles, mumps, and rubella (MMR) immunization rates during the measles outbreak in Calgary and Edmonton of 2014 stratified by four area-level socio-demographic indicators. This study also leverages this epidemiological data to assess the equity aspect of emergency measures instituted regarding immunization in those two cities. METHODS: A mixed-methods comparative case study analysis methodology was employed to assess the neighbourhood-level immunization statuses before (2013), during (2014), and after (2015) an active measles outbreak in Calgary and Edmonton, Alberta, Canada. The epidemiological one-dose by age-2 MMR coverage data were stratified using four socio-demographic indicators: median household income, %-homeownership, %-Aboriginal population, and %-immigrant population. Document and content analysis was utilized to investigate the outbreak mitigation strategies deployed in each city. RESULTS: The measles outbreak of 2013/2014 involved the entirety of Alberta and led to both provincial and city-specific interventions in which Calgary deployed three mass immunization clinics in 2014, where Edmonton did not. The Calgary coverage data showed an increase in coverage inequalities across all indicators and the Edmonton data showed mixed results in terms of equity gains/losses. Calgary's additive intervention of three mass immunization clinics in 2014 appears to have contributed to both the higher gross immunization rates in Calgary (90.77%) and an inequitable increase in coverage rates as compared with Edmonton (88.96%), in most cases. CONCLUSION: Public health policy-makers must be cognizant that large-scale public health efforts must be optimized for accessibility across all socio-economic levels to ensure public and population health gains are realized equitably.
RéSUMé: OBJECTIFS: Cette étude porte sur les taux de vaccination contre la rougeole, la rubéole et les oreillons (RRO) durant l'éclosion de rougeole de 2014 à Calgary et à Edmonton, stratifiés selon quatre indicateurs sociodémographiques régionaux. L'étude se sert aussi de ces données épidémiologiques pour évaluer l'équité des mesures de vaccination d'urgence instituées dans les deux villes. MéTHODE: À l'aide d'une analyse comparative d'études de cas à méthodes mixtes, nous avons évalué les statuts vaccinaux par quartier avant (2013), pendant (2014) et après (2015) une éclosion active de rougeole survenue à Calgary et Edmonton, en Alberta, au Canada. Les données épidémiologiques relatives à la couverture du vaccin RRO, administré en une dose avant l'âge de 2 ans, ont été stratifiées à l'aide de quatre indicateurs sociodémographiques : le revenu médian des ménages, le pourcentage d'accession à la propriété, le pourcentage de la population autochtone et le pourcentage de la population immigrante. Nous avons fait appel à l'analyse documentaire et à l'analyse de contenu pour étudier les stratégies d'atténuation de l'éclosion déployées dans chaque ville. RéSULTATS: L'éclosion de rougeole de 2013-2014 a sévi partout en Alberta et a donné lieu à des interventions à l'échelle de la province et des villes; trois cliniques de vaccination de masse ont été déployées à Calgary en 2014, mais aucune à Edmonton. Selon les données relatives à la couverture vaccinale à Calgary, il y a eu une augmentation des inégalités dans la couverture pour tous les indicateurs; selon les données pour Edmonton, les résultats en matière de gains ou de pertes d'équité ont été mitigés. L'ajout de trois cliniques de vaccination de masse à Calgary en 2014 semble avoir contribué à la fois aux taux de vaccination bruts plus élevés à Calgary (90,77 %) et à une hausse inéquitable des taux de couverture comparativement à Edmonton (88,96 %) dans la plupart des cas. CONCLUSION: Les responsables des politiques de santé publique doivent être conscients qu'il faut optimiser les efforts de santé publique à grande échelle pour que toutes les classes socioéconomiques en bénéficient, afin que les gains réalisés en santé publique et en santé des populations soient équitables.
Assuntos
Sarampo , Caxumba , Alberta/epidemiologia , Pré-Escolar , Surtos de Doenças/prevenção & controle , Humanos , Imunização , Sarampo/epidemiologia , Sarampo/prevenção & controle , Vacina contra Sarampo-Caxumba-Rubéola , Caxumba/epidemiologia , Caxumba/prevenção & controleRESUMO
Los países de las Américas, con apoyo de la Organización Panamericana de la Salud (OPS), han logrado avances notables al proporcionar a los niños y las niñas una protección general contra las enfermedades prevenibles mediante vacunación. Los niveles sostenidos de elevadas coberturas nacionales de vacunación, la erradicación de la poliomielitis, la interrupción de la transmisión endémica del virus del sarampión y las iniciativas más recientes en favor de la eliminación de la rubéola y el síndrome de rubéola congénita son hitos continentales de este progreso. En la actualidad, los países administran vacunas a grupos etarios distintos de los incluidos en los programas tradicionales de inmunización infantil. La introducción de la vacuna estacional contra la gripe en los adultos en riesgo; la vacunación de adolescentes y adultos, hombres y mujeres, para la eliminación de la rubéola, y la definición de la carga de enfermedad del cáncer cervicouterino son las actividades que apoyan la necesidad fundamental de efectuar una transición de los programas nacionales de inmunización infantil a programas de inmunización de la familia. Una de las funciones de la OPS en su apoyo a los países es difundir información que destaque el progreso de la Región y los desafíos que enfrenta. Con ese fin, publica varios documentos técnicos relacionados con la inmunización, tales como los boletines de inmunización, los módulos de capacitación en inmunización y la serie de guías prácticas sobre rubéola, sarampión, tétanos neonatal, poliomielitis, vacuna pentavalente y fiebre amarilla.
Assuntos
Imunização , Vacinação , COVID-19 , Vacinas contra COVID-19 , Sarampo , Vacina contra Sarampo-Caxumba-Rubéola , Vírus da Rubéola , Vacina contra Rubéola , Difteria , Vacina contra Difteria, Tétano e Coqueluche , Febre Amarela , Rotavirus , Vacinas contra Rotavirus , Poliovirus , Coqueluche , Caxumba , Meningite , Vacina contra Coqueluche , Vacina contra Caxumba , Parotidite , Vacina contra Febre Amarela , Vacinas , Programas de Imunização , América , Doenças Preveníveis por Vacina , Indicadores Básicos de Saúde , Região do CaribeRESUMO
BACKGROUND: Universal varicella vaccination has proven to be cost-effective (CE) in countries where implemented. However, this has not been evaluated for Mexico. METHODS: The yearly disease burden (varicella cases/deaths, outpatient visits, and hospitalizations) was derived from Mexican seroprevalence data adjusted to the 2020 population. The yearly economic burden was calculated by combining disease with Mexican unit cost data from both health care and societal perspectives. Four different vaccination strategies were evaluated: (1) 1 dose of varicella vaccine at 1 year old; (2) 2 doses at 1 and 6 years; (3) 1 dose of varicella vaccine at 1 year, and quadrivalent measles-mumps-rubella-varicella vaccine at 6 years; (4) 2 doses of measles-mumps-rubella-varicella vaccine at 1 and 6 years. We developed an economic model for each vaccination strategy where 20 consecutive birth cohorts were simulated. Vaccination impact (number of avoided cases/deaths) was evaluated for a 20-year follow-up period based on vaccine effectiveness (87% and 97.4% for 1 and 2 doses), and assuming a 95% coverage. We estimated annual costs saved, incremental cost-effectiveness ratio, and costs per life year gained. RESULTS: Avoided cases during the 20-year follow-up with 1, and 2 doses were 20,570,722 and 23,029,751, respectively. Strategies 1 and 2 were found to be cost saving, and strategy 3 to be CE. Strategy 4 was not CE. Strategies 1 and 2 would allow saving annually $53.16 and $34.41 million USD, respectively, to the Mexican society. CONCLUSIONS: Universal varicella vaccination, using 1 dose or 2 doses, would result in a cost-beneficial and CE public health intervention in Mexico.
Assuntos
Varicela , Sarampo , Caxumba , Rubéola (Sarampo Alemão) , Varicela/epidemiologia , Varicela/prevenção & controle , Vacina contra Varicela , Análise Custo-Benefício , Humanos , Lactente , Sarampo/prevenção & controle , Vacina contra Sarampo-Caxumba-Rubéola , México/epidemiologia , Caxumba/prevenção & controle , Rubéola (Sarampo Alemão)/prevenção & controle , Estudos Soroepidemiológicos , VacinaçãoRESUMO
BACKGROUND: Mumps deafness causes serious problems, and incidence data are needed to identify its disease burden. However, such data are limited, and the reported incidence is highly variable. Nationwide studies in Japan with a large age range are lacking. METHODS: This was a retrospective observational investigation of the 2005-2017 mumps burden using employment-based health insurance claims data. Data were analyzed for 5,190,326 people aged 0-64 years to estimate the incidence of mumps deafness. RESULTS: Of 68,112 patients with mumps (36,423 males; 31,689 females), 102 (48 males; 54 females) developed mumps deafness-an incidence of 15.0 per 10,000 patients (1 in 668 patients). Fifty-four (52.9%) patients had mumps deafness in childhood (0-15 years), and 48 (47.1%) had mumps deafness in adolescence and adulthood (16-64 years); most cases occurred in childhood, the peak period for mumps onset. The incidence of mumps deafness per 10,000 patients was 73.6 in adolescence and adulthood, 8.4 times higher than the incidence of 8.8 in childhood (P < 0.001). In childhood, the incidence of mumps deafness was 7.2 times higher among 6-15-year-olds (13.8; 95% CI, 10.2-18.2) than among 0-5-year-olds (1.9; 95% CI, 0.6-4.5), and this difference was statistically significant (P < 0.001). No sex difference was observed. CONCLUSIONS: The incidence of mumps deafness per 10,000 patients aged 0-64 years was 15.0 (1 in 668 patients). A secondary risk of deafness following mumps virus infection was identified not only for children, but also for adolescents and adults.
Assuntos
Surdez , Seguro , Caxumba , Adolescente , Adulto , Criança , Pré-Escolar , Surdez/epidemiologia , Surdez/etiologia , Feminino , Humanos , Incidência , Lactente , Recém-Nascido , Japão/epidemiologia , Masculino , Pessoa de Meia-Idade , Caxumba/complicações , Caxumba/epidemiologia , Adulto JovemRESUMO
Antecedentes: las paperas son una infección viral que se transmite por contacto directo, gotitas y fómites. Irak es testigo de varias epidemias de paperas. Objetivo: Informar sobre la última epidemia de paperas 2015-2016. Métodos: El lado de Bagdad de Al-Rusafa fue seleccionado al azar de dos lados de Bagdad. Se llevó a cabo una revisión de los datos del Departamento de Salud Pública de la Dirección de Salud de Bagdad / Al-Rusafa. Los datos fueron todos los casos notificados de paperas para los años 2015-2016. Resultados: Los casos registrados de paperas fueron 9780 y 33728 para 2015 y 2016, respectivamente. La edad máxima en 2015 y 2016 fue de 5 a 14 años. Los picos de casos de paperas se registraron en octubre, diciembre de 2015 y enero de 2016, y desaparecieron en junio de 2016. Conclusiones: La epidemia de paperas fue clara en Bagdad. La lucha social juega un papel en el desarrollo de la epidemia.
Background: Mumps is a viral infection transmitted by direct contact, droplet infection and fomites. Iraq witnesses several epidemics of mumps. Objective: To report on last epidemic of mumps 2015- 2016. Methods: Al-Rusafa side of Baghdad was selected randomly from two sides of Baghdad. A review of data from department of public health, Directorate of Health of Baghdad / Al-Rusafa was carried out. The data was all the notification cases of mumps for the years 2015-2016. Results: The registered cases of mumps were 9780 and 33728 for 2015 and 2016, respectively. The peak age in 2015 and 2016 was 5-14 year. The peaks mumps cases were in October, December 2015 and January 2016, and disappear in June 2016. Conclusions: Epidemic of mumps was clear in Baghdad. Social strife plays a role in developing the epidemic.
Assuntos
Humanos , Criança , Adolescente , Equidade em Saúde , Epidemias/prevenção & controle , Caxumba/diagnósticoRESUMO
BACKGROUND: Mumps vaccination coverage is low in Japan, partly because of its voluntary nature. Although pediatric cases of mumps virus infection are captured by the National Epidemiological Surveillance of Infectious Diseases program under the Infectious Disease Law, there are currently no data regarding the occurrence of mumps and its complications in adults. METHODS: We investigated the annual incidence rates of mumps and its complications based on health insurance reimbursement data for 5,209,660 individuals aged 0-64 years for 2005-2017, obtained from JMDC Inc., to estimate the mumps-related disease burden during this period. RESULTS: There were three mumps outbreaks (2006, 2010, and 2016) during 2005-2017. The annual incidence of mumps was highest in individuals aged 0-5 years (808-3,792 per 100,000 persons), followed by those aged 6-15 years (658-2,141 per 100,000 persons). The incidence of mumps was higher in females than in males (male/female ratio, 0.90). Among mumps-related complications, the overall incidence (per 1,000 mumps cases) was highest for orchitis (6.6), followed by meningitis (5.8), deafness (1.3), pancreatitis (0.5), and encephalitis (0.3). No cases of oophoritis were noted. The overall incidence of mumps-related complications was 2.5 times higher in males than in females. CONCLUSIONS: This study revealed the disease burden due to mumps and its complications in Japan during 2005-2017. These data suggest the need for mumps-prevention measures in adolescents and adults, as well as in children.
Assuntos
Efeitos Psicossociais da Doença , Surtos de Doenças , Caxumba/complicações , Caxumba/epidemiologia , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Humanos , Incidência , Lactente , Recém-Nascido , Reembolso de Seguro de Saúde , Japão/epidemiologia , Masculino , Pessoa de Meia-Idade , Caxumba/economia , Adulto JovemRESUMO
During January 1-March 2, 2018, the number of mumps cases among adults reported to the Chicago Department of Public Health (CDPH) doubled compared with the same period in 2017. In response, CDPH created a supplementary questionnaire to collect additional information on populations affected and potential transmission routes. An epidemiologic analysis of routine and supplementary data, including spatiotemporal analysis, was performed to describe mumps cases reported to CDPH during 2018. A fourfold increase in mumps cases was reported during 2018 compared with 2017, with men who have sex with men (MSM) and persons living with human immunodeficiency virus (HIV) infection disproportionately represented among cases. A spatiotemporal, residential cluster was identified in a 9-square-mile area within six adjacent communities. The majority of persons affected were MSM, and this area was visited by many other persons with mumps diagnoses. Spatiotemporal analyses could be used in real time to identify case clusters to target public health response efforts, including to guide recommendations for additional measles, mumps, and rubella (MMR) vaccine and to identify specific transmission venues.
Assuntos
Surtos de Doenças , Infecções por HIV/epidemiologia , Disparidades nos Níveis de Saúde , Homossexualidade Masculina/estatística & dados numéricos , Caxumba/epidemiologia , Adulto , Chicago/epidemiologia , Análise por Conglomerados , Surtos de Doenças/prevenção & controle , Feminino , Humanos , Masculino , Vacina contra Sarampo-Caxumba-Rubéola/administração & dosagem , Caxumba/prevenção & controle , Fatores de Risco , Análise Espaço-TemporalRESUMO
ANTECEDENTES: La inmunización es una de las intervenciones en salud pública más costo efectivas y rentables. Sarampión, parotiditis y rubeola (SPR) son enfermedades virales, que pueden causar complicaciones y consecuencias graves, especialmente en niños desnutridos e inmunodeprimidos; siendo importante destacar, que estas enfermedades son prevenibles mediante la vacunación. El resurgimiento de las infecciones por el virus de las paperas entre personas previamente vacunados con dos dosis, ha planteado preocupaciones en el mundo, sobre la ausencia de inmunidad a largo plazo después de la vacunación contra esta enfermedad y ha aperturado discusiones sobre nuevas estrategias para mitigar el riesgo de brotes futuros, incluyendo la posibilidad de implementar una tercera dosis de la vacuna SPR como respuesta a un brote epidémico, frente al cual, además surge la necesidad de estudios adicionales que evalúen la protección a largo plazo proporcionada por tres dosis de las vacunas SPR, así como la rentabilidad de la implementación de ésta intervención. OBJETIVO: El objetivo de la presente revisión sistemática es sintetizar evidencias científicas sobre la seguridad y efectividad frente a parotiditis de la vacuna Sarampión, Rubéola, Paperas (SPR) en personas mayores de 5 años. METODOLOGÍA: La búsqueda sistemática se realizó en la base de datos de Medline (PubMed), Lilacs y Cochrane Library fueron formuladas una estrategia de búsqueda para la pregunta PICO de la revisión, no se aplicaron filtros de fecha ni idiomas, la búsqueda abordó la evidencia publicada hasta 12 de marzo del 2020. La selección de título y resumen y extracción de datos fue realizada por un solo revisor. RESULTADOS: La búsqueda identificó 9 estudios: 1 revisión sistemática, 1 ensayo clínico y 7 estudios observacionales. La revisión incluyó tres estudios en niños y adolescentes. El ensayo clínico se realizó en adultos y los estudios observacionales fueron en adultos y en niños. CONCLUSIONES: No se observan diferencias estadísticamente significativas entre los niños que reciben una tercera dosis con los que reciben dos dosis. La vacuna SPR en niños mayores de 5 años presenta pocos y leves reacciones adversas. En adultos sanos, la tercera dosis de SPR no presenta reacciones adversas graves o largo plazo. En población militar, la aplicación de vacuna SPR no se asocia con aparición de diabetes mellitus tipo 1. (AU)
Assuntos
Humanos , Pré-Escolar , Criança , Vacina contra Sarampo-Caxumba-Rubéola/administração & dosagem , Sarampo/prevenção & controle , Caxumba/prevenção & controle , Avaliação da Tecnologia Biomédica , Avaliação em SaúdeRESUMO
BACKGROUND: Health care workers (HCWs) and students are at increased risk for blood borne infections and vaccine preventable diseases (VPDs). The aim of this study was to determine the seroprevalence of antibodies against measles, rubella, mumps, varicella zoster virus (VZV), hepatitis A and B viruses among HCWs and students and to determine whether there are differences according to gender and age group. METHODS: Information about characteristics of the 1053 participants, history of disease and vaccination status were collected using a structured questionnaire. Serum samples were tested for antibodies by commercial immunoenzymatic assays. RESULTS: Seropositivity rates were 57.1% for measles, 74% for mumps, 96.3% for rubella, 93.7% for VZV, 33.9% for hepatitis A virus and 92.2% for hepatitis B virus. Susceptibility rates among participants 18-26, 27-38 and >38 years of age were statistically significant for measles (46%, 18.6% and 0%; p < 0.001) and mumps (27.1%, 12.9% and 21.4%; p < 0.05), respectively. CONCLUSION: Low seropositivity rates for measles, mumps and HAV are important findings. For other diseases other than VZV, it is thought that vaccination without pre-screening is more appropriate. Healthcare institutions should have policies for screening and vaccination of their staff and students.
Assuntos
Varicela/epidemiologia , Pessoal de Saúde , Hepatite A/epidemiologia , Hepatite B/epidemiologia , Programas de Rastreamento , Sarampo/epidemiologia , Caxumba/epidemiologia , Rubéola (Sarampo Alemão)/epidemiologia , Estudantes de Medicina , Estudantes de Enfermagem , Vacinação , Adolescente , Adulto , Varicela/prevenção & controle , Análise Custo-Benefício , Ensaio de Imunoadsorção Enzimática , Feminino , Pessoal de Saúde/estatística & dados numéricos , Hepatite A/prevenção & controle , Hepatite B/prevenção & controle , Humanos , Masculino , Programas de Rastreamento/métodos , Sarampo/prevenção & controle , Pessoa de Meia-Idade , Caxumba/prevenção & controle , Estudos Retrospectivos , Rubéola (Sarampo Alemão)/prevenção & controle , Estudos Soroepidemiológicos , Estudantes de Medicina/estatística & dados numéricos , Estudantes de Enfermagem/estatística & dados numéricos , Inquéritos e Questionários , Turquia/epidemiologia , Vacinação/métodos , Adulto JovemRESUMO
Seroprevalence studies on measles, mumps, and rubella immunoglobulin G (IgG) antibodies after the implementation of the measles-mumps-rubella (MMR) vaccine are lacking in Kuwait. This study is an age-stratified serological study to assess the herd immunity to measles, mumps, and rubella among the young Kuwaiti population to evaluate the effectiveness of the MMR vaccine. IgG antibody titers to mumps, measles, and rubella were determined with commercial immune-assay in serum samples of 1000 Kuwaitis aged 5 to 20 years. The highest level of seropositivity was to measles (94.6%), which was significantly higher in females than in males. The highest seronegativity was for mumps (29%). The percentage of the young Kuwaiti population who were serologically positive for all the components of the MMR vaccine was 47%, and 2% of the individuals were without any protective antibodies to measles, mumps, and rubella. Females aged 5 to 10 years were best protected to rubella; however, seronegativity in 8.2% of 11- to 20-year-old females makes them vulnerable to rubella virus infection and congenital complications during pregnancy. The study provided insight into the effect of the MMR vaccine on seroprevalence of antibodies against measles, mumps, and rubella in Kuwait, which will contribute to the global knowledge base of vaccine coverage and help to inform elimination strategies. The findings strengthen the need for a third dose of MMR vaccine and catch-up campaigns for the young Kuwaiti population to increase vaccination coverage and prevent waning immunity, especially among those who received only one dose of the vaccine during childhood.